Mitochondrial Dysfunction at the Center of Cancer Therapy
Mitochondrial Dysfunction at the Center of Cancer Therapy
复制标题
DOI：
10.1089/ars.2019.7898
复制
发表时间：
2019-11-04
影响因子：
6.6
通讯作者：
Taneja, Reshma
中科院分区：
文献类型：
--
作者：
Chiu, Hsin Yao;Tay, Emmy Xue Yun;Taneja, Reshma
最新进展：目前，癌症治疗的金标准是化疗、放疗和手术。然而，这些治疗的疗效在不同的癌细胞中有所不同。有人认为线粒体可能是这些不同反应的中心。在过去的十年中，在理解癌症中不同类型的线粒体功能障碍方面取得了重大进展。通过对潜在机制的研究，开发了更有效的治疗方案。关键问题：我们总结了癌症进展中的各种线粒体功能障碍，这些障碍导致了治疗方案的发展。目前的尿道靶向治疗和挑战进行了讨论。未来方向：为了解决癌症的“根源”，利用肿瘤靶向治疗靶向癌症干细胞可能是有价值的。对线粒体运输等其他领域的研究可能为癌症治疗提供新的见解。此外，常见的抗生素可以被探索为丝裂霉素，合成的致死筛选可以用来克服癌细胞的可塑性。
Recent Advances: Currently, the gold standard for cancer treatment is chemotherapy, radiation, and surgery. However, the efficacy of these treatments varies across different cancer cells. It has been suggested that mitochondria may be at the center of these diverse responses. In the past decade, significant advances have been made in understanding distinct types of mitochondrial dysfunctions in cancer. Through investigations of underlying mechanisms, more effective treatment options are developed. Critical Issues: We summarize various mitochondria dysfunctions in cancer progression that have led to the development of therapeutic options. Current mitochondrial-targeted therapies and challenges are discussed. Future Directions: To address the "root" of cancer, utilization of mitochondrial-targeted therapy to target cancer stem cells may be valuable. Investigation of other areas such as mitochondrial trafficking may offer new insights into cancer therapy. Moreover, common antibiotics could be explored as mitocans, and synthetic lethality screens can be utilized to overcome the plasticity of cancer cells.